Related Experiment Videos

Smoking diminishes the beneficial effect of statins: observations from the landmark trials

H J Milionis1, E Rizos, D P Mikhailidis

  • 1Department of Clinical Biochemistry, Royal Free and University College Medical School (University College London), UK.

Angiology
|September 26, 2001
PubMed

Insights

Smoking significantly worsens outcomes for ischemic heart disease, even with statin treatment. Quitting smoking offers greater protection than statins alone, highlighting smoking cessation as crucial for cardiovascular health.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trials
  • Public Health

Background:

  • Landmark statin trials demonstrated significant reductions in ischemic heart disease (IHD) morbidity and mortality.
  • The adverse impact of smoking on cardiovascular outcomes within these trials is often underestimated.
  • Smoking poses a substantial risk factor for IHD events, irrespective of statin therapy.

Purpose of the Study:

  • To quantify the independent and combined effects of smoking and statin therapy on IHD outcomes.
  • To compare the relative risks of IHD events between smokers and nonsmokers, with and without statin treatment.
  • To emphasize the critical role of smoking cessation in cardiovascular disease prevention.

Main Methods:

  • Analysis of data from landmark statin trials, stratifying participants by smoking status and treatment group (placebo vs. statin).
  • Calculation of relative risks for ischemic heart disease events in primary and secondary prevention settings.
  • Comparison of event rates between smokers and nonsmokers, and between treated and untreated individuals.

Main Results:

  • Smoking markedly increased the risk of IHD events in both placebo and statin groups.
  • In primary prevention, smokers faced a 74-86% higher risk than nonsmokers in placebo groups.
  • In secondary prevention, smokers faced a 23-61% higher risk than nonsmokers in placebo groups.
  • Untreated nonsmokers had event risks similar to smokers receiving statins.
  • The best outcomes were observed in nonsmokers treated with statins; the highest risk was in smokers on placebo.

Conclusions:

  • Smoking exerts a profound adverse effect on cardiovascular outcomes, comparable to or exceeding the benefits of statin therapy in some contexts.
  • Statin treatment significantly reduces events in smokers, but nonsmokers on statins achieve the best outcomes.
  • Clinicians and patients must recognize the severe harm of smoking and prioritize smoking cessation alongside evidence-based treatments like statins for optimal cardiovascular risk reduction.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Lifestyle Factors and Health01:20

Lifestyle Factors and Health

Lifestyle factors play a critical role in maintaining overall health and preventing chronic diseases. Key elements, such as regular physical activity, a nutritious diet, and abstinence from smoking, can significantly enhance physical, mental, and emotional well-being while reducing the risk of several life-threatening conditions.
Benefits of Physical Activity
Physical activity, whether through structured exercise or casual activities like walking, biking, or dancing, is a cornerstone of a...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...